Education
About Us
Working with TipRanks
Follow Us
Vericel Corp (VCEL)
NASDAQ:VCEL
VCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.24 - $63.00
Previous CloseN/A
Volume83.17K
Average Volume (3M)833.66K
Market Cap
$1.70B
Enterprise Value$2.13B
Total Cash (Recent Filing)$116.88M
Total Debt (Recent Filing)$101.54M
Price to Earnings (P/E)265.5
Beta1.13
Next Earnings
Nov 06, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding50,460,205
10 Day Avg. Volume658,308
30 Day Avg. Volume833,661
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)9.19
Price to Sales (P/S)11.31
P/FCF Ratio-461.58
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue8.54
Enterprise Value/Gross Profit11.62
Enterprise Value/Ebitda131.44
Forecast
1Y Price Target
$55.17Price Target Upside66.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Market ExpansionMACI Arthro expands the potential surgeon target base from 5,000 up to 7,000, enhancing the focus on knee cartilage procedures.
Product AdoptionMACI Arthro adoption is unlocking growth in femoral condyle and trochlear defects while activating entirely new surgeon cohorts.
Revenue GrowthBiopsy pipelines, MACI Arthro training momentum, and a 30% salesforce expansion ahead of peak volumes support the call that the company can hit its low-20% MACI revenue growth target in 2025.
Bears Say
Market ExpectationsDespite favorable conversion dynamics and ASP increases, MACI revenue growth is expected to be steady mid-to-high teens, which might not meet higher Street estimates.
Product ImpactAround 60% of surgeons surveyed expect no change to MACI volumes despite Arthro as an option, suggesting limited impact on growth from new product offerings.
Stock PerformanceVCEL shares are down approximately 42% year-to-date following two softer quarters, indicating performance challenges.
Vericel News
VCEL FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was $29.24 and its highest was $63.00 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is $1.70B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is Nov 06, 2025 which is in 28 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Jul 31, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.032 by $0.022.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is >-0.01.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 50,460,205 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.032. Following the earnings report the stock price went down -14.068%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in VCEL
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.17 (66.63% Upside)
$55.17 (66.63% Upside)
Blogger Sentiment
Bullish
VCEL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 7.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.36%
12-Months-Change
Fundamentals
Return on Equity
2.59%
Trailing 12-Months
Asset Growth
15.60%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth across key segments and robust profitability metrics. Despite a few challenges such as Epicel cancellations and adjusted guidance for Burn Care, the overall business outlook remains positive with promising growth indicators, especially in the MACI segment.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$55.17
▲(66.63% Upside)
Technical Analysis
Ownership Overview
1.06% Insiders
36.95% Mutual Funds
4.62% Other Institutional Investors
35.41% Public Companies and
Individual Investors